Argenx stock gains as Jefferies lifts price target and Q2 2026 beat stays in focus
Published on 09/03/2026 at 15:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx stock (ISIN NL0010832176) is trading close to a fresh 52-week high after a recent analyst update and strong Q2 2026 figures kept the immunology specialist firmly on investors radar as of September 3, 2026.
Jefferies raises target as Argenx challenges Teva in celiac disease
According to an analysis reported by finanzen.net on September 3, 2026, Jefferies has reiterated its Buy rating on Argenx and lifted the price target from 1,140.00 USD to 1,215.00 USD for the NASDAQ-listed shares.
The same Jefferies commentary, summarized by finanzen.net, highlights that study data from a competing celiac disease therapy developed by Teva do not convincingly surpass Argenx candidate FB102, which leads the analyst to draw positive conclusions for Argenx competitive position in this indication.
Stock near 52-week high after Q2 2026 earnings beat
A MarketBeat alert noted that Argenx shares recently hit a new 52-week high, trading as high as 1,069.00 USD intraday and last changing hands near 1,057.92 USD, compared with a prior close of 1,028.51 USD for the NASDAQ listing, underscoring the strong price momentum around the latest results.
As detailed by MarketBeat on September 2, 2026, Argenx reported Q2 2026 earnings per share of 7.32 USD, beating analyst consensus of 5.86 USD by 1.46 USD.
The same MarketBeat earnings summary indicates that Q2 2026 revenue reached 1.54 billion USD, ahead of the 1.45 billion USD forecast, which represents an outperformance of about 90 million USD versus expectations in the quarter.
More on Argenx stock and fundamentals
Read additional Argenx coverage and corporate disclosures to better understand how the companys immunology portfolio and recent earnings performance shape the risk-reward profile of Argenx stock.
Margins, guidance and analyst expectations
MarketBeat data for the latest quarter show that Argenx achieved a net margin of 32.19 percent and a return on equity of 43.59 percent in Q2 2026, indicating a highly profitable expansion phase as the company scales its therapies.
In addition, sell side analysts tracked in the same MarketBeat overview expect Argenx SE to deliver 29.04 USD in earnings per share for the current fiscal year, providing a reference point for how Q2 2026 performance fits into the broader earnings trajectory.
For investors, the combination of double digit top line growth, a Q2 2026 earnings beat of 1.46 USD per share versus consensus, and robust margins explains why Argenx stock is trading toward the upper end of its 52 week range.
Immunology pipeline supported by AI driven discovery
A recent release by BenchSci published on September 2, 2026 announced a two year enterprise agreement under which BenchSci will deploy its EMET agentic research environment inside Argenx to support AI driven preclinical drug discovery.
BenchSci describes EMET as a software environment designed to help biopharma companies identify and prioritize preclinical targets more efficiently, and the partnership with Argenx underscores the immunology groups commitment to using data and automation to expand its pipeline.
While the financial terms of the agreement were not disclosed in the press release, the duration of two years and the focus on preclinical research suggest that Argenx aims to complement its existing antibody based portfolio with earlier stage assets identified via AI assisted methods.
Representative product focus from Vyvgart franchise
One of Argenx key commercial pillars is its Fc fragment based antibody therapy Vyvgart, which targets the neonatal Fc receptor to help reduce pathogenic IgG antibodies in certain autoimmune diseases.
The Vyvgart franchise, including subcutaneous and intravenous formulations, has become central to Argenx revenue development in recent reporting periods, and investors often track patient uptake and geographic expansion to gauge the sustainability of the growth profile.
Although the current search hits focus more on earnings and analyst views than on detailed unit numbers for Vyvgart in Q2 2026, the strong revenue and margin figures reported by MarketBeat for the quarter indicate that key commercial products such as Vyvgart continue to perform well in Argenx portfolio.
Argenx stock price snapshot and trading context
According to a recent quote overview referenced in MarketBeat on September 2, 2026, Argenx stock closed at 1,028.51 USD on NASDAQ and traded intraday up to 1,069.00 USD, a level described as a new 1 year high for the listing.
That same snapshot indicated that the last traded level near 1,057.92 USD was significantly above the prior close of 1,028.51 USD, reflecting a price increase of around 2.9 percent during the session and underscoring sustained investor interest following the Q2 2026 earnings beat and positive analyst commentary.
Argenx stock key data
- Company: Argenx SE
- ISIN: NL0010832176
- Ticker: ARGX
- Trading venue: NASDAQ
- Price (as of September 2, 2026): 1,028.51 USD
- Market capitalization: Not specified in available same day sources
- Sector / Industry: Biotechnology / Immunology
- Index membership: Not specified in available same day sources
